Immune cell boost: new hope for kids with tough neuroblastoma?
NCT ID NCT06450041
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a new approach for children and young adults with relapsed or hard-to-treat neuroblastoma. Patients receive donor immune cells (NK cells) along with standard chemotherapy and an antibody therapy. The goal is to see if this combination can shrink tumors or stop the cancer from growing. The study will enroll 62 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
donor natural killer (NK) cells, temozolomide, irinotecan, dinutuximab, and sargramostim
What this could lead to
If successful, this combination could offer a new treatment option for children with neuroblastoma that has come back or not responded to standard therapy.
What could go wrong
This is a phase 2 trial with only 62 participants, so results are preliminary. The treatment involves strong chemotherapy and immune cells, which can cause serious side effects like low blood counts and organ damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Boston Children's Hospital, Dana-Farber Cancer Institute.
NOT_YET_RECRUITINGBoston, Massachusetts, 02115, United States
Contact
-
C.S Mott Children's Hospital
NOT_YET_RECRUITINGAnn Arbor, Michigan, 48109, United States
Contact
-
Children's Hospital Colorado
NOT_YET_RECRUITINGAurora, Colorado, 80045, United States
Contact
-
Children's Hospital Los Angeles
RECRUITINGLos Angeles, California, 90027-0700, United States
Contact
-
Children's Hospital of Philadelphia
RECRUITINGPhiladelphia, Pennsylvania, 19104-4318, United States
Contact
-
Cincinnati Children's Hospital Medical Center
NOT_YET_RECRUITINGCincinnati, Ohio, 45229-3039, United States
Contact
-
Comer Children's Hospital, University of Chicago
NOT_YET_RECRUITINGChicago, Illinois, 60614, United States
Contact Email: •••••@•••••
-
Cook Children's Medical Center
RECRUITINGFort Worth, Texas, 76104, United States
Contact
-
Nationwide Children's Hospital
RECRUITINGColumbus, Ohio, 43205, United States
Contact
-
Seattle Children's Hospital
NOT_YET_RECRUITINGSeattle, Washington, 98105, United States
Contact
-
St. Jude Children's Research Hospital
RECRUITINGMemphis, Tennessee, 38105, United States
Contact
-
UCSF Benioff Children's Hospital
NOT_YET_RECRUITINGSan Francisco, California, 94143, United States
Contact
-
University of Texas Southwestern
RECRUITINGDallas, Texas, 75235, United States
Contact